A drug discovery and development company with “first-in-class” drugs for respiratory diseases
Investors
Verona Pharma is listed on the London Stock Exchange under the VRP.L ticker and on the Frankfurt Xetra platform under the I9S ticker. Read more here about investing in Verona Pharma
Verona Pharma shares
Pipeline
Verona Pharma is focused on developing new drugs for a range of respiratory diseases. See our Pipeline
Downloads
Interim Report for the six months ended 30 June 2016
Circular for Placing to raise c. £44.7 million
Annual Report for the year ended 31 December 2015
Publication in The Lancet Respiratory Medicine
Partners
A key component of Verona Pharma’s business strategy is out-licensing its “first-in-class” drug programmes to suitable development and commercialisation partners. To discuss partnering opportunities, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.
Events and Media
Follow the links below for more information about specific events:
Verona Pharma plc, 3 More London Riverside. London SE1 2RE
Email:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Tel: +44 (0)203 283 4200
To provide feedback or report problems with the website:
This email address is being protected from spambots. You need JavaScript enabled to view it.